Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Other solid neoplasm 2Other hematologic neoplasm 1Lymphoid 1CNS 1Breast 1

Conditions

Optic Nerve Glioma 1Medulloblastoma 1Familial ependymoma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 147Radiotherapy 91Cyclophosphamide 53Magnetic Resonance Spectroscopy 43Radiation 42Bevacizumab 38Irinotecan 34Filgrastim 29Radiosurgery 27Specimen Handling 25Nivolumab 25Carboplatin 24Topotecan 23Etoposide 22fludarabine 20Surgical Procedures, Operative 20pembrolizumab 19Vorinostat 18Vincristine 18Melphalan 17Granulocyte Colony-Stimulating Factor 17sargramostim 15Peripheral Blood Stem Cell Transplantation 14Ipilimumab 14Drug Therapy 13temsirolimus 12Sirolimus 12Radiotherapy, Intensity-Modulated 12O(6)-benzylguanine 12Everolimus 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Amplified Fragment Length Polymorphism Analysis × CNS × Clear all
NCT00360854 2013-09-20

Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

National Cancer Institute (NCI)

Phase 1 Unknown
48 enrolled
CNS

Familial ependymoma, Astrocytoma, Medulloblastoma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡